Bhavin Shriprasad Shukla

Title: Bhavin Shriprasad Shukla: Innovator in Pharmaceutical Chemistry

Introduction

Bhavin Shriprasad Shukla is a notable inventor in the field of pharmaceutical chemistry, based in Gujarat, India. He has made significant contributions to the development of innovative compounds and processes that have potential therapeutic applications. With a focus on DPP-IV inhibitors, his work is paving the way for advancements in diabetes treatment.

Latest Patents

Bhavin Shukla holds 2 patents that showcase his expertise in synthesizing novel pharmaceutical compounds. His latest patents include the development of new salts of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine, specifically gentisate, adipate, and trifluoroacetic acid salts. These inventions also describe new crystalline and amorphous forms of the compound, as well as novel crystalline salt forms of hydrochloride and besylate, along with processes for their preparation and isolation.

Another significant patent involves the synthesis of β-amino acid derivatives through a novel process that utilizes borane-containing reducing agents. This process leads to the resolution of racemic β-amino compounds into pure stereoisomers, further enhancing the potential for therapeutic applications.

Career Highlights

Bhavin Shukla is currently associated with Cadila Healthcare Limited, a prominent player in the pharmaceutical industry. His work at the company emphasizes the importance of innovation in drug development and the synthesis of complex chemical compounds.

Collaborations

Throughout his career, Bhavin has collaborated with talented professionals, including Bipin Pandey and Mayank Ghanshyambhai Dave. These collaborations have fostered a creative environment that encourages the exchange of ideas and expertise in pharmaceutical research.

Conclusion

Bhavin Shriprasad Shukla is a distinguished inventor whose contributions to pharmaceutical chemistry are noteworthy. His innovative patents and collaborative efforts are making a significant impact in the field, particularly in the development of new therapeutic agents.